Bausch + Lomb (BLCO) said Thursday it is voluntarily recalling the intraocular lenses on its enVista platform after reports of complications.

The company said it received an increased number of reports of toxic anterior segment syndrome related to its enVista Aspire, enVista Envy, and certain enVista monofocal intraocular lenses. The syndrome is an inflammatory reaction inside the eye typically caused by the introduction of toxic substances into the eye.

The company said that the cause of the incidents "could not immediately be explained."

"These reports represent an extremely small percentage of implanted lenses, with a positive prognosis for everyone involved," said Brent Saunders, chairman and CEO of Bausch + Lomb. "We look forward to identifying a root cause and bringing the enVista platform back to market."

Bausch + Lomb shares were down by more than 4% in premarket trading.